![](/img/cover-not-exists.png)
296 A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies
Shimizu, T., Aida, H., Horobin, J., Keegan, M., Padval, M., Poli, A., Hashii, C., Nakagawa, K.Volume:
50
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(14)70422-8
Date:
November, 2014
File:
PDF, 77 KB
english, 2014